Literature DB >> 18468492

Vagus nerve stimulation for intractable epilepsy in tuberous sclerosis complex.

Philippe Major1, Elizabeth A Thiele.   

Abstract

OBJECTIVES: The aim of the study described here was to characterize the efficacy and safety of vagus nerve stimulation in a population of patients with tuberous sclerosis complex (TSC) and intractable epilepsy.
METHODS: This retrospective study comprised 16 patients with TSC who underwent implantation of a vagus nerve stimulator for treatment of intractable epilepsy.
RESULTS: The average age at vagus nerve stimulator implantation was 15 years (range: 2-44, SD: 12.5) and the average duration of follow-up on VNS was 4 years (range: 0.5-8.6, SD: 2.3). Outcome was rated class I (>80% seizure frequency reduction) in 3 (19%), class II (50-79% reduction) in 5 (31%), class III (<50% reduction) in 2 (13%), class IV (magnet benefit only) in 1 (6%), and class V (no improvement) in 5 (31%) patients. Intermittent magnet use was effective in aborting seizures in 8 (50%). Five (31%) patients reported an improved level of functioning.
CONCLUSION: The findings suggest that the vagus nerve stimulation can be an effective and safe therapy for patients with TSC with intractable epilepsy.

Entities:  

Mesh:

Year:  2008        PMID: 18468492     DOI: 10.1016/j.yebeh.2008.04.001

Source DB:  PubMed          Journal:  Epilepsy Behav        ISSN: 1525-5050            Impact factor:   2.937


  10 in total

Review 1.  Epilepsy secondary to tuberous sclerosis: lessons learned and current challenges.

Authors:  Romina Moavero; Caterina Cerminara; Paolo Curatolo
Journal:  Childs Nerv Syst       Date:  2010-04-01       Impact factor: 1.475

Review 2.  Rescue therapies for seizures.

Authors:  Valeriya S Poukas; John R Pollard; Christopher Todd Anderson
Journal:  Curr Neurol Neurosci Rep       Date:  2011-08       Impact factor: 5.081

3.  Vagal nerve stimulation for drug-resistant epilepsies in different age, aetiology and duration.

Authors:  Gabriella Colicchio; Domenico Policicchio; Giulia Barbati; Elisabetta Cesaroni; Filomena Fuggetta; Mario Meglio; Fabio Papacci; Franco Rychlicki; Massimo Scerrati; Nelia Zamponi
Journal:  Childs Nerv Syst       Date:  2010-01-21       Impact factor: 1.475

4.  The natural history of epilepsy in tuberous sclerosis complex.

Authors:  Catherine J Chu-Shore; Philippe Major; Susana Camposano; David Muzykewicz; Elizabeth A Thiele
Journal:  Epilepsia       Date:  2009-12-22       Impact factor: 5.864

Review 5.  Vagus nerve stimulation in the treatment of refractory epilepsy.

Authors:  Andrew H Milby; Casey H Halpern; Gordon H Baltuch
Journal:  Neurotherapeutics       Date:  2009-04       Impact factor: 7.620

Review 6.  Optimal management of seizures associated with tuberous sclerosis complex: current and emerging options.

Authors:  Shelly Wang; Aria Fallah
Journal:  Neuropsychiatr Dis Treat       Date:  2014-10-23       Impact factor: 2.570

7.  Epilepsy in tuberous sclerosis complex: Findings from the TOSCA Study.

Authors:  Rima Nabbout; Elena Belousova; Mirjana P Benedik; Tom Carter; Vincent Cottin; Paolo Curatolo; Maria Dahlin; Lisa D Amato; Guillaume Beaure d'Augères; Petrus J de Vries; José C Ferreira; Martha Feucht; Carla Fladrowski; Christoph Hertzberg; Sergiusz Jozwiak; John A Lawson; Alfons Macaya; Ruben Marques; Finbar O'Callaghan; Jiong Qin; Valentin Sander; Matthias Sauter; Seema Shah; Yukitoshi Takahashi; Renaud Touraine; Sotiris Youroukos; Bernard Zonnenberg; Anna Jansen; John C Kingswood
Journal:  Epilepsia Open       Date:  2018-12-21

8.  Current role of surgery for tuberous sclerosis complex-associated epilepsy.

Authors:  Nicola Specchio; Giusy Carfi Pavia; Luca de Palma; Alessandro De Benedictis; Chiara Pepi; Marta Conti; Carlo Efisio Marras; Federico Vigevano; Paolo Curatolo
Journal:  Pediatr Investig       Date:  2022-02-21

Review 9.  Review of the treatment options for epilepsy in tuberous sclerosis complex: towards precision medicine.

Authors:  Susanne Schubert-Bast; Adam Strzelczyk
Journal:  Ther Adv Neurol Disord       Date:  2021-07-17       Impact factor: 6.570

10.  Long-term cannabidiol treatment for seizures in patients with tuberous sclerosis complex: An open-label extension trial.

Authors:  Elizabeth A Thiele; E Martina Bebin; Francis Filloux; Patrick Kwan; Rachael Loftus; Farhad Sahebkar; Steven Sparagana; James Wheless
Journal:  Epilepsia       Date:  2021-12-27       Impact factor: 6.740

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.